Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Liabilities and Shareholders Equity (2018 - 2025)

Addex Therapeutics' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $8.0 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 34.68% to $8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.0 million, a 16.04% decrease, with the full-year FY2025 number at $7.7 million, down 37.03% from a year prior.
  • Liabilities and Shareholders Equity came in at $8.0 million for Q4 2025, down from $9.2 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $29.7 million in Q1 2021, with the low at $3.8 million in Q1 2024.
  • Historically, Liabilities and Shareholders Equity has averaged $13.1 million across 5 years, with a median of $11.2 million in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 64.83% in 2022 and later surged 176.01% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $24.4 million in 2021, then tumbled by 64.83% to $8.6 million in 2022, then crashed by 39.13% to $5.2 million in 2023, then skyrocketed by 132.93% to $12.2 million in 2024, then plummeted by 34.68% to $8.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ADXN at $8.0 million in Q4 2025, $9.2 million in Q3 2025, and $10.3 million in Q2 2025.